ProCE Banner Activity

CheckMate 648: Expanded Analysis of First-line Nivolumab + CT vs Nivolumab/Ipilimumab vs CT in Advanced Esophageal Squamous Cell Carcinoma

Slideset Download
Conference Coverage
Improved survival with nivolumab + chemotherapy and nivolumab + ipilimumab vs chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma and at least 1% PD-L1 expression assessed by either tumor cell staining or CPS.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab